Fifty years of the National Health Service 1948-1998: A personal history of progress in the treatment of cancer

Clinical Oncology

Volumn 11, Issue 1, 1999, Pages 55-60

  Halnan, K E ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CISPLATIN; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

AUTOMATION; CANCER; GENE THERAPY; HISTORY OF MEDICINE; HUMAN; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

EID: 0033000839     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.1999.9011     Document Type: Review

References (56)

1. G. Hilton: Obituary. BMJ. iii:1971;378.
2. McCready R. A celebration of the life of Professor Sir David Smithers. 1977;British Institute of Radiology, London: p. 66-7.
3. Smithers D W. The X-ray treatment of accessible cancer. 1946;Edward Arnold, London:
4. Paterson R. The treatment of malignant disease by radiotherapy. 1948;Edward Arnold, London:
5. Meredith W J. Radium dosage: the Manchester system. 1947;Livingstone, London:
6. Mitchell J S. Studies in radiotherapeutics. 1960;Blackwell, Oxford:
7. Wilkinson J F, Fletcher F. Effect of b-chlorethylamine hydrochlorides in leukaemia, Hodgkin's disease, and polycythaemia vera. Lancet. ii:1947;540-545.
8. Nabarro J DN. Nitrogen mustard therapy in the reticuloses. Br J Radiol. 24:1951;507-510.
9. Court-Brown W M, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. BMJ. ii:1965;1327-1332.
10. Pochin E E, Hilton G, Halnan K E. The role of radioiodine in treatment of carcinoma of the thyroid. Br J Radiol. 29:1956;297.
11. .Wilson, G, M. The treatment of thyrotoxicosis. Edinburgh: Royal College of Physicians, 1967.
12. Easson E C, Jones B E, Mackenzie L A. Treatment of polycythaemia rubra vera by phosphorus-32. Br J Radiol. 28:1955;405.
13. Halnan K E, Russell H. Polycythaemia vera. Comparison of survival and causes of death in patients managed with and without radiotherapy. Lancet. ii:1965;760-763.
14. Halnan K E, Pochin E E. The use of iodine-132 for thyroid function tests. Br J Radiol. 31:1958;581-583.
15. Ellis F. Treatment of the larynx by tantalum wire. J Laryngol. 75:1961;811-820.
16. Johns H E, Bates L M, Watson T A. The Saskatchewan 1000 curie cobalt-60 unit. Br J Radiol. 25:1952;296-318.
17. Miller C W. The continuing evolution of linear accelerators. Br J Radiol. 35:1961;182.
18. Del Regato J A. Ralston Paterson. Int J Radiat Oncol Biol Phys. 13:1987;1081-1091.
19. Halnan K E. Ralston Paterson. Int J Radiat Oncol Biol Phys. 14:1988;513-514.
20. Stewart J G. The clinical significance of dose distribution problems. Br J Radiol. 35:1962;743-745.
21. Applications of modern technology in radiotherapy: treatment simulators. 1976;BIR, London:
22. Newbery G R, Bewley D K. The performance of the Medical Research Council 8 MeV linear accelerator. Br J Radiol. 38:1955;241-251.
23. Greene D. Linear accelerators for radiation therapy. 1986;Adam Hilger, Bristol:
24. Wood C AP, Boag J W. MRC Research on the radiotherapy of oral cancer. 1950;HMSO, London:
25. Gray L H, Conger A D, Ebert M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
26. Thomlinson R H, Gray L H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 9:1955;539.
27. Churchill-Davidson L, Sanger C, Thomlinson R H. High pressure oxygen and radiotherapy. Lancet. i:1955;1091.
28. Cade I S, McEwan J B, Halnan K E. Hyperbaric oxygen: Medical Research Council trials in carcinomas of the bladder and cervix. Br J Radiol. 51:1978;876-878.
29. Doll R. Radiation hazards: 25 years of collaborative research. Br J Radiol. 54:1981;179-186.
30. .United Nations. Report of the United Nations Scientific Committee on the effects of atomic radiation. General Assembly official records 13th session, supplement no. 17(A-3838). New York: UN,1958.
31. Halnan K E. Risks of radio-iodine treatment for thyrotoxicosis. BMJ. 287:1983;1821.
32. Rock Carling E, Windeyer B W, Smithers D W. British practice in radiotherapy. 1955;Butterworth, London:
33. .Raven, R, editor. Cancer, vols 1-7.
34. O'Connell D, Joslin C A, Ramsey N W. A new remotely controlled unit for the treatment of uterine carcinoma. Lancet. ii:1965;570.
35. Orr J S, Halnan K E, Hope C S. Computing in radiotherapy. Scot Med J. 15:1970;370.
36. Hope C S, Orr J S, Halnan K E. The role of computers in radiotherapy. Vienna: International Atomic Energy Agency. 1968;. p. 100-12.
37. Fowler J F, Morgan R L, Sylvester J A. Experiments with fractionated X-ray treatment of the skin of pigs. Fractionation up to 28 days. Br J Radiol. 36:1963;188.
38. Catterall M, Bewley D K. Fast neutrons in the treatment of cancer. London: Academic Press. 1979.
39. Greene D. A fast neutron source for radiotherapy. Nature. 202:1964;404.
40. Greene D, Thomas R L. An experimental unit for fast neutron radiotherapy. Br J Radiol. 41:1968;455.
41. Duncan W, Arnott S J, Batterman J J. Fast neutrons in the treatment of head and neck cancers: the results of a multi-centre trial. Radiother Oncol. 2:1984;293-300.
42. Beaney R, McCready R. Tumour imaging in cancer. Sikora K, Price P, Halnan KE. Treatment of cancer. 1995;135-136 Chapman and Hall, London:
43. Adams G E, Fowler J F, Wardman P. Hypoxic cell sensitizers in radiobiology and radiotherapy. Br J Cancer. 37:1966.
44. DeVita V T, Serpick A, Carbone P P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 73:1970;881.
45. Halnan K E, Todd I, Brewin T B. Early clinical experience with bleomycin in the United Kingdom in a series of 105 patients. BMJ. iv:1972;635-638.
46. Einhorn L H, Donohue J P. Cisplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 87:1977;293-298.
47. Spencer A, O'Brien S G, Goldman J M. Chronic myeloid leukaemia - optimum therapy. Br J Haematol. 91:1995;2-7.
48. Bonadonna G, Rossi A, Valagassa P. The CMF programme for operative breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer. 39:1977;2904-2915.
49. Lancet. 339:1992;1-15.
50. Field S B, Hand J W. An introduction to the practical aspects of clinical hyperthermia. 1990;Taylor and Francis, London:
51. Saunders M, Dische S. Continuous hyperfractionated accelerated radiotherapy in non-small cell carcinoma of the bronchus. 1989;British Institute of Radiology, London: p. 47-51.
52. Peto R, Pike M C, Armitage P. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Part I: Introduction and design. Part II: Analysis. Br J Cancer. 34:1976;1-39.
53. Sikora K, Gullick W J. Molecular biology. Price P, Sikora K, Halnan K E. Treatment of cancer, 3rd ed. 1995;17-31 Chapman and Hall, London:
54. Ponder B AJ. The gene causing multiple endocrine neoplasia type 2 (MEN-2). Ann Med. 26:1994;199-203.
55. Population and Health. 1998.
56. Cancer Registration Statistics, Scotland 1986-95. 1998.